Novartis Ag (NVSEF) Total Current Liabilities (2009 - 2025)

Novartis Ag has disclosed Total Current Liabilities across 12 years of filings, most recently posting $27.3 billion for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $27.3 billion, down 4.93% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.3 billion (down 4.93% YoY), and the FY2025 annual result was $27.3 billion, down 4.93% from the prior year.
• Total Current Liabilities came in at $27.3 billion for Q4 2025 at Novartis Ag, down from $31.7 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $31.9 billion in Q2 2023 to a low of $25.2 billion in Q2 2021.
• The 5-year median for Total Current Liabilities is $28.2 billion (2022), against an average of $28.5 billion.
• Across the five-year window, Total Current Liabilities climbed 15.42% in 2023 and dropped 13.47% in 2024, its largest moves.
• Novartis Ag's Total Current Liabilities stood at $30.2 billion in 2021, then dropped by 5.14% to $28.7 billion in 2022, then slipped by 7.91% to $26.4 billion in 2023, then climbed by 8.72% to $28.7 billion in 2024, then declined by 4.93% to $27.3 billion in 2025.
• The last three Total Current Liabilities figures came in at $27.3 billion (Q4 2025), $31.7 billion (Q2 2025), and $28.7 billion (Q4 2024), per Business Quant data.